Maze Therapeutics, Inc.

Maze Therapeutics, a clinical-stage biopharmaceutical company, announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. These appointments are made at a crucial time as the company progresses its development programs, with upcoming data readouts for MZE829 and MZE782 in late 2026 and 2027, respectively. Both new board members bring extensive clinical, research, and biopharmaceutical leadership experience to support Maze's mission.

Maze Therapeutics reported a net loss of $44.7 million for Q2 2026, an increase from $33.7 million in Q2 2025. Year-to-date 2026 net loss was $68.9 million, compared to $66.5 million in the prior year. The company significantly bolstered its capital, raising $144.6 million through an underwritten registered equity offering and securing an initial $40.0 million from a new $200.0 million Hercules Term Loan Facility. R&D expenses rose to $34.9 million in Q2 2026, and G&A expenses increased to $13.1 million. The company believes its existing cash, cash equivalents, and marketable securities of $494.9 million are sufficient to fund operations for at least one year.

Maze Therapeutics, Inc. reported a net loss of $44.7 million ($0.76 per share) for the second quarter ended June 30, 2026. The company maintained a strong balance sheet with $494.9 million in cash, cash equivalents, and marketable securities, extending its expected cash runway into 2029. Key operational updates include MZE829 Phase 2 HORIZON trial data expected in late 2026 or early 2027, and the initiation of the MZE782 Phase 2 CIPheR trial for PKU with topline data anticipated in 2027.

Maze Therapeutics reported Q2 2026 financial results and provided updates on its clinical pipeline. The company announced that enrollment in the Phase 2 HORIZON trial of MZE829 is on track, with data expected in late 2026 or early 2027. The Phase 2 CIPheR trial of MZE782 in PKU has been initiated, with topline data anticipated in 2027, and a Phase 2 trial for MZE782 in CKD is set to begin in H1 2027. Maze maintains a strong balance sheet with $494.9 million in cash, cash equivalents, and marketable securities, extending its expected cash runway into 2029.

Maze Therapeutics announced that its Chief Executive Officer, Jason Coloma, Ph.D., will participate in two upcoming investor conferences. He is scheduled to present at the 2026 Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10. The company, a clinical-stage biopharmaceutical firm, is focused on developing small molecule precision medicines for kidney and metabolic diseases, with key programs MZE829 and MZE782 in Phase 2 development. Live webcasts of the presentations will be accessible via the company's investor relations website.

Maze Therapeutics announced that Amy Bachrodt resigned from her position as Senior Vice President, Finance, effective June 1, 2026. The company stated that her resignation was not a result of any disagreement regarding operations, policies, practices, or financial reporting. Following her departure, Misbah Tahir, the current Chief Financial Officer, will assume the role of principal accounting officer.

Maze Therapeutics reported a net loss of $24.2 million for Q1 2026, a reduction from $32.8 million in Q1 2025, driven by $20.0 million in license revenue. The company secured an initial $40.0 million term loan from a new $200.0 million facility in February 2026. Additionally, subsequent to the quarter end, Maze Therapeutics completed a $144.7 million equity offering and received a $20.0 million milestone payment, which are expected to fund operations for at least one year.

Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial for MZE829 in broad AMKD, demonstrating a clinically meaningful reduction in proteinuria and supporting advancement to a pivotal trial in H1 2027. The company also announced plans to initiate two Phase 2 trials for MZE782 in PKU and CKD by mid-2026 and H2 2026, respectively. For Q1 2026, Maze reported a net loss of $24.2 million on $20.0 million in license revenue, and a strong balance sheet with $362.9 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2029.

Maze Therapeutics reported positive topline data from its Phase 2 HORIZON trial of MZE829 in broad APOL1-Mediated Kidney Disease (AMKD), demonstrating proof-of-concept and supporting advancement into a pivotal trial in H1 2027. The company also announced plans to initiate two Phase 2 trials for MZE782 in PKU and CKD in 2026. Financially, Maze reported a Q1 2026 net loss of $24.2 million, an improvement from the prior year, and a strong balance sheet with $528 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2029.

Maze Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, with a record date of April 13, 2026. Stockholders will vote on the election of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026. The board will transition from 10 to 8 members, with Neil Exter and Catherine Angell Sohn not seeking re-election, and new committee appointments planned.